Chicago, Illinois 60637


The purpose of the proposed research is to test and validate an artificial intelligence-based Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI) interpretation and identification of clinically significant tumor site(s).


Inclusion Criteria: - Patients with known or suspected prostate cancer who have been referred to the Department of Radiology at the University of Chicago Medical Center for a diagnostic MRI exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate. - Written informed consent. Exclusion Criteria: - Patients incapable of giving informed written consent; - Patients who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher; - Patients with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders. - Prisoners; - Minor children (under the age of 18 years old).



Primary Contact:

Principal Investigator
Aytekin Oto, MD
University of Chicago

Ambereen Yousuf
Phone: (773) 702-6003

Backup Contact:


Location Contact:

Chicago, Illinois 60637
United States

Ambereen Yousuf
Phone: 773-702-6003

Site Status: Recruiting

Data Source:

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.